A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms PemCiGem
- 31 Jan 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020.
- 31 Jan 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.
- 05 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.